Erythropoiesis-driven regulation of hepcidin in human red cell disorders is better reflected through concentrations of soluble transferrin receptor rather than growth differentiation factor 15

American Journal of Hematology

Volumn 89, Issue 4, 2014, Pages 385-390

  Fertrin, Kleber Yotsumoto ^a   Lanaro, Carolina ^a   Franco Penteado, Carla Fernanda ^a   de Albuquerque, Dulcinéia Martins ^a   de Mello, Mariana Rezende Bandeira ^a   Pallis, Flávia Rubia ^a   Bezerra, Marcos André Cavalcanti ^b   Hatzlhofer, Betania Lucena Domingues ^c   Olbina, Gordana ^d   Olalla Saad, Sara Terezinha ^a   da Silva Araújo, Aderson ^c   Westerman, Mark ^d   Costa, Fernando Ferreira ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^c Hematology and Hemotherapy Center HEMOPE Foundation   (Brazil)

^d Intrinsic LifeSciences LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; C REACTIVE PROTEIN; CLARITHROMYCIN; CYANOCOBALAMIN; ERYTHROPOIETIN; FERRITIN; GROWTH DIFFERENTIATION FACTOR 15; HEMOGLOBIN; HEPCIDIN; HYDROXYUREA; INTERLEUKIN 6; IRON; LACTATE DEHYDROGENASE; OMEPRAZOLE; TRANSFERRIN RECEPTOR;

ARTICLE; BETA THALASSEMIA; BLOOD CELL COUNT; CONTROLLED STUDY; CYANOCOBALAMIN DEFICIENCY; CYTOKINE PRODUCTION; ERYTHROCYTE DISORDER; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HELICOBACTER INFECTION; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; HYPERFERRITINEMIA; IRON ABSORPTION; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REDUCTION; REGULATORY MECHANISM; RETICULOCYTE COUNT; SICKLE CELL ANEMIA; THALASSEMIA INTERMEDIA; VITAMIN SUPPLEMENTATION;

ANEMIA, IRON-DEFICIENCY; CASE-CONTROL STUDIES; ERYTHROCYTES; ERYTHROPOIESIS; FEMALE; GROWTH DIFFERENTIATION FACTOR 15; HEMATOLOGIC DISEASES; HEPCIDINS; HUMANS; IRON; IRON OVERLOAD; MALE; RECEPTORS, TRANSFERRIN; TRANSFERRIN;

EID: 84897401236     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23649     Document Type: Article

References (40)

1. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-2093.
2. Tamary H, Shalev H, Perez-Avraham G, et al. Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I. Blood 2008;112:5241-5244.
3. Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007;13:1096-1101.
4. Casanovas G, Swinkels DW, Altamura S, et al. Growth differentiation factor 15 in patients with congenital dyserythropoietic. J Mol Med 2011;89:811-816.
5. Musallam KM, Taher AT, Duca L, et al. Levels of growth differentiation factor-15 are high and correlate with clinical. Blood Cells Mol Dis 2011;47:232-234.
6. Santini V, Girelli D, Sanna A, et al. Hepcidin levels and their determinants in different types of myelodysplastic. PLoS One 2011;6:e23109.
7. Inati A, Musallam KM, Cappellini MD, et al. Nontransferrin-bound iron in transfused patients with sickle cell disease. Int J Lab Hematol 2011;33:133-137.
8. Welsh JB, Sapinoso LM, Kern SG, et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci USA 2003;100:3410-3415.
9. Bauskin AR, Brown DA, Kuffner T, et al. Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res 2006;66:4983-4986.
10. Hochholzer W, Morrow DA, Giugliano RP. Novel biomarkers in cardiovascular disease: Update 2010. Am Heart J 2010;160:583-594.
11. Cohen AR, Porter JB. Transfusion and iron chelation in thalassemia and sickle cell anemia. In: Steinberg MH, Forget BG, Higgs DR, et al., editors. Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management. Cambridge University Press; New York, USA, 2001. pp 979-1027.
12. Vichinsky E, Butensky E, Fung E, et al. Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia. Am J Hematol 2005;80:70-74.
13. Hankins JS, Smeltzer MP, McCarville MB, et al. Patterns of liver iron accumulation in patients with sickle cell disease and thalassemia with iron overload. Eur J Haematol 2010;85:51-57.
14. Ghoti H, Goitein O, Koren A, et al. No evidence for myocardial iron overload and free iron species in multitransfused patients with sickle/beta-thalassaemia. Eur J Haematol 2010;84:59-63.
15. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271-1276.
16. Kroot JJ, Kemna EH, Bansal SS, et al. Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: Need for standardization. Haematologica 2009;94:1748-1752.
17. Kroot JJ, van Herwaarden AE, Tjalsma H, et al. Second round robin for plasma hepcidin methods: First steps toward harmonization. Am J Hematol 2012;87:977-983.
18. Melis MA, Cau M, Congiu R, et al. A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron. Haematologica 2008;93:1473-1479.
19. Young MF, Glahn RP, Ariza-Nieto M, et al. Serum hepcidin is significantly associated with iron absorption from food and supplemental sources in healthy young women. Am J Clin Nutr 2009;89:533-538.
20. Ganz T, Olbina G, Girelli D, et al. Immunoassay for human serum hepcidin. Blood 2008;112:4292-4297.
21. Kearney SL, Nemeth E, Neufeld EJ, et al. Urinary hepcidin in congenital chronic anemias. Pediatr Blood Cancer 2007;48:57-63.
22. Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, et al. Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood 2011;117:E218-E225.
23. Huff RL, Hennessy TG, Austin RE, et al. Plasma and red cell iron turnover in normal subjects and in patients having various hematopoietic disorders. J Clin Invest 1950;29:1041-1052.
24. Samson D, Halliday D, Chanarin I. Reversal of ineffective erythropoiesis in pernicious anaemia following vitamin B12 therapy. Br J Haematol 1977;35:217-224.
25. Casanovas G, Spasic MV, Casu C, et al. The murine growth differentiation factor 15 is not essential for systemic iron homeostasis in phlebotomized mice. Haematologica 2013;98:444-447.
26. Pasricha SR, Frazer DM, Bowden DK, et al. Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with beta-thalassemia major: a longitudinal study. Blood 2013;122:124-133.
27. Waalen J, von Lohneysen K, Lee P, et al. Erythropoietin, GDF15, IL6, hepcidin and testosterone levels in a large cohort of elderly individuals with anaemia of known and unknown cause. Eur J Haematol 2011;87:107-116.
28. Finkenstedt A, Widschwendter A, Brasse-Lagnel CG, et al. Hepcidin is correlated to soluble hemojuvelin but not to increased GDF15 during pregnancy. Blood Cells Mol Dis 2012;48:233-237.
29. Nemeth E, Valore EV, Territo M, et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003;101:2461-2463.
30. Rachmilewitz EA, Shohet SB, Lubin BH. Lipid membrane peroxidation in beta-thalassemia major. Blood 1976;47:495-505.
31. Hebbel RP, Eaton JW, Balasingam M, et al. Spontaneous oxygen radical generation by sickle erythrocytes. J Clin Invest 1982;70:1253-1259.
32. Cighetti G, Duca L, Bortone L, et al. Oxidative status and malondialdehyde in beta-thalassaemia patients. Eur J Clin Invest 2002;32 Suppl 1:55-60.
33. Walter PB, Fung EB, Killilea DW, et al. Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol 2006;135:254-263.
34. Tanno T, Porayette P, Sripichai O, et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood 2009;114:181-186.
35. Skikne BS, Punnonen K, Caldron PH, et al. Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: A prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index. Am J Hematol 2011;86:923-927.
36. Beguin Y. Soluble transferrin receptor for the evaluation of erythropoiesis and iron status. Clin Chim Acta 2003;329:9-22.
37. Pasricha SR, Frazer DM, Bowden DK, et al. Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with beta-thalassemia major: A longitudinal study. Blood 2013;122:124-133.
38. Li H, Rybicki AC, Suzuka SM, et al. Transferrin therapy ameliorates disease in beta-thalassemic mice. Nature medicine 2010;16:177-182.
39. Guo SL, Casu C, Gardenghi S, et al. Reducing TMPRSS6 ameliorates hemochromatosis and beta-thalassemia in mice. J Clin Invest 2013;123:1531-1541.
40. Kautz L, Nemeth E, Ganz T. The erythroid factor erythroferrone and its role in iron homeostasis. Am J Hematol 2013;88:E24.